Aruna Bio Receives U.S. Patent for Neural Exosomes Reducing Brain Inflammation

BOSTON and ATHENS, Ga., Aug. 19, 2024 — Aruna Bio, Inc., a pioneering company in neural exosome-based therapeutics, has announced a significant advancement in their ongoing research efforts. The U.S. Patent and Trademark Office has allowed U.S. Patent Application No. 17/238760, titled "Neural Cell Extracellular Vesicles." This patent includes method of use claims related to Aruna Bio’s lead program, AB126, targeting neuro-inflammatory diseases.

AB126, an exosome derived from proprietary neural stem cells, has shown promising results in reducing brain inflammation. The patent encompasses broad claims for the application of AB126 in treating various conditions where neuroinflammation is the key pathological factor. This includes a wide range of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis (ALS), prion disease, motor neuron disease (MND), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA).

The patent also includes multiple methods of administration for AB126. These methods encompass intravenous, intranasal, intrathecal, intraperitoneal, oral, and direct delivery into the brain, providing diverse options for treatment delivery depending on the patient's needs and the specific condition being treated.

Dr. Steven Stice, Co-Founder and Chief Scientific Officer of Aruna Bio, expressed enthusiasm about the development. He remarked, “We are excited to announce the allowance of this method of use patent, as it validates the broad utility of our proprietary exosome platform for the treatment of neuroinflammatory conditions. As we continue to strengthen our robust patent portfolio, expanding its breadth of claims across indications and extending its protection, we are also preparing to advance in the clinic.”

Aruna Bio is at the forefront of transforming central nervous system (CNS) treatment through its cutting-edge neural exosome platform. The company focuses on neurological conditions such as ALS, Alzheimer's disease, and stroke. AB126, their leading product, exhibits various biological activities, including the ability to cross the blood-brain barrier, provide neuroprotection, and reduce neuro-inflammation. These characteristics make AB126 a potentially versatile treatment for a wide spectrum of neurological diseases.

Aruna Bio operates an in-house cGMP facility, which supports the development of their pipeline from early stages through clinical trials. This facility ensures that they maintain high standards of quality and regulatory compliance throughout the development process. The company's strategic approach includes utilizing their exosome platform for drug delivery and investigating combination therapies. This comprehensive strategy aims to address the unmet needs in CNS treatment, offering hope to patients affected by debilitating neurological conditions.

Aruna Bio’s efforts are not only focused on treatment development but also on creating a strong intellectual property base to protect their innovations. The recent patent allowance marks a significant milestone in this journey, reinforcing the potential of their therapeutic platform and laying the groundwork for future clinical advancements.